<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368445</url>
  </required_header>
  <id_info>
    <org_study_id>MP433</org_study_id>
    <nct_id>NCT01368445</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine&#xD;
      hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice&#xD;
      daily in patients with seasonal allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 12-hour reflective total nasal symptoms score(TNSS) for the entire 14-day study period compared to placebo</measure>
    <time_frame>14 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in instantaneous total nasal symptoms score (TNSS) for the entire 14-day study period compared to placebo</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 14 in Roland Quality of Life Questionnaire (RQLQ )compared to placebo</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Direct Visual Nasal Exams</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">617</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MP03-36 Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azelastine hydrochloride 0.15%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP03-36 and Placebo Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azelastine hydrochloride 0.15% and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azelastine 0.1%, Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azelastine 0.1%, Nasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Nasal Sapray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0mg, 2 sprays per nostril twice daily AM &amp; PM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine hydrochloride 0.15% Nasal Spray</intervention_name>
    <description>1644 mcg, 2 sprays per nostril twice daily AM &amp; PM)</description>
    <arm_group_label>MP03-36 Nasal Spray</arm_group_label>
    <arm_group_label>Placebo Nasal Sapray</arm_group_label>
    <other_name>astepro .15%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine hydrochloride 0.15% and Placebo</intervention_name>
    <description>822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)</description>
    <arm_group_label>MP03-36 and Placebo Nasal Spray</arm_group_label>
    <arm_group_label>Placebo Nasal Sapray</arm_group_label>
    <other_name>Astepro.15%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelastine 0.1%, Nasal Spray</intervention_name>
    <description>1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM &amp; PM)</description>
    <arm_group_label>Azelastine 0.1%, Nasal Spray</arm_group_label>
    <arm_group_label>Placebo Nasal Sapray</arm_group_label>
    <other_name>Astepro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients 12 years of age and older&#xD;
&#xD;
          -  Provide written informed consent/pediatric assent. If the patient is a minor, a parent&#xD;
             or legal guardian must give written informed consent&#xD;
&#xD;
          -  Screening Visit: Have a 12-hour reflective total nasal symptoms score ( TNSS) of at&#xD;
             least 8 out of a possible 12 and a congestion score of 2 or 3 on Day -7&#xD;
&#xD;
          -  Randomization Visit: Have a 12-hour reflective total nasal symptoms score (TNSS) (AM&#xD;
             or PM) of at least 8 on 3 separate assessments (one of which was within 2 days of Day&#xD;
             1, and can include the morning of Day 1) during the Lead-in Period. In addition, an AM&#xD;
             or PM nasal congestion score of 2 or 3 must have been recorded on 3 separate&#xD;
             assessments (one of which was within 2 days of Day 1, and can include the morning of&#xD;
             Day 1).&#xD;
&#xD;
          -  Must have taken at least 10 doses of study medication during the lead-in period&#xD;
&#xD;
          -  Randomization Visit: An instantaneous (TNSS) of ≥ 8 before beginning the onset of&#xD;
             action assessment on Day 1&#xD;
&#xD;
          -  Willing and able to comply with the study requirements&#xD;
&#xD;
          -  At least a 2-year history of seasonal allergic rhinitis (SAR) during the fall pollen&#xD;
             allergy season&#xD;
&#xD;
          -  The presence of IgE-mediated hypersensitivity to local fall pollen confirmed by a&#xD;
             positive response to either skin prick or intradermal testing within the last year. A&#xD;
             positive response is defined as a wheal diameter of at least 3 mm larger than the&#xD;
             control for the skin prick test or at least 7 mm larger than the control for the&#xD;
             intradermal test.&#xD;
&#xD;
          -  General good health and free of any disease or concomitant treatment that could&#xD;
             interfere with the interpretation of the study results as determined by the&#xD;
             investigator or the sponsor's medical officer&#xD;
&#xD;
          -  Patients receiving immunotherapy injections (antigen desensitization) must be on a&#xD;
             stable maintenance regimen for at least 30 days before the first study visit&#xD;
             (adjustments to regimen following a brief period of missed injections does not&#xD;
             preclude participation). Patients who are on maintenance doses of sublingual&#xD;
             immunotherapy may be considered for the trial on a case-by-case basis after discussion&#xD;
             with the sponsor's medical monitor or designee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of any investigational drug within 30 days prior to Day -7. No investigational&#xD;
             products are permitted for use during the conduct of this study&#xD;
&#xD;
          -  Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol&#xD;
             or sucralose (Splenda® brand sweetener)&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Women of childbearing potential who are not abstinent and not practicing a medically&#xD;
             acceptable method of contraception&#xD;
&#xD;
          -  Respiratory tract infections within two weeks prior to Day -7&#xD;
&#xD;
          -  Respiratory Infections requiring oral antibiotic treatment two weeks prior to Day -7&#xD;
&#xD;
          -  Other nasal disease(s) likely to affect deposition of intranasal medication, such as&#xD;
             sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal&#xD;
             structural abnormalities&#xD;
&#xD;
          -  Patients with asthma (with the exception of mild, intermittent asthma)&#xD;
&#xD;
          -  Patients with significant pulmonary disease&#xD;
&#xD;
          -  Patients with a known history of alcohol or drug abuse&#xD;
&#xD;
          -  Existence of any surgical or medical condition, which in the opinion of the&#xD;
             investigator or sponsor, might significantly alter the absorption, distribution,&#xD;
             metabolism, or excretion of study drug&#xD;
&#xD;
          -  Clinically relevant abnormal physical findings within 1 week of randomization which,&#xD;
             in the opinion of the investigator, would interfere with the objectives of the study&#xD;
             or that may preclude compliance with the study procedures&#xD;
&#xD;
          -  Planned travel outside the study area during the study period&#xD;
&#xD;
          -  Family members and employees should be excluded&#xD;
&#xD;
          -  Patients who received prohibited medications within specified timepoints in the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AABI Associates Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Research Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Medical Group</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Associates of CA</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The William Storms Allergy Clinic</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Allergy and Asthma P.C.</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy and Asthma</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Asthma and Allergy, P.C.</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates, Inc.</name>
      <address>
        <city>N. Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Asthma and Allergy Center, PC</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Allergy, Asthma &amp; Immunology</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Institue of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Institute of Allergy and Asthma</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Consultants of NJ-PA, P.C</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <zip>19426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Research Center</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Clinical Immunology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Associates Research Dept.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas,</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

